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The current review article describes the functional relationship between tumor-associated
macrophages (TAM) as key cellular contributors to cancer malignancy on the one hand and
macrophage-colony-stimulating factor (M-CSF or CSF-1) as an important molecular contrib-
utor on the other.We recapitulate the available data on expression of M-CSF and the M-CSF
receptor (M-CSFR) in human tumor tissue as constituents of a stromal macrophage signa-
ture and on the limits of the predictive and prognostic value of plasma M-CSF levels. After
providing an update on current insights into the nature ofTAM heterogeneity at the level of
M1/M2 phenotype andTAM subsets, we give an overview of experimental evidence, based
on genetic, antibody-mediated, and pharmacological disruption of M-CSF/M-CSFR signal-
ing, for the extent to which M-CSFR signaling can not only determine theTAM quantity, but
can also contribute to shaping the phenotype and heterogeneity of TAM and other related
tumor-infiltrating myeloid cells (TIM). Finally, we review the accumulating information on
the – sometimes conflicting – effects blocking M-CSFR signaling may have on various
aspects of cancer progression such as tumor growth, invasion, angiogenesis, metastasis,
and resistance to therapy and we thereby discuss in how far these different effects actually
reflect a contribution of TAM.
Keywords: M-CSF, CSF-1, M-CSFR, CSF-1R, tumor-associated macrophages, M1, M2, cancer progression
INTRODUCTION
CANCER MALIGNANCY
Ca ncer is a complex multi-step process, in which normal cells
acquire a certain growth advantage via a process analogous to Dar-
winian evolution. These cellular changes can occur under many
different circumstances, which contributes to the heterogeneity
and variability of the occurrence, development, and outcome of
neoplastic disease (1). The traits required for malignant growth
include self-sufficiency from external growth signals, insensitiv-
ity to negative growth signals, resistance to apoptosis, limitless
replicative potential, sustained angiogenesis, acquisition of tissue
invasiveness, and metastasis. Recently, genetic instability, altered
Abbreviations: DAMP, damage-associated molecular pattern; EGF, epidermal
growth factor; Fizz1, found in inflammatory zone 1; GAST, gastrointestinal stro-
mal tumor; G-CSF, granulocyte-colony-stimulating factor; GM-CSF, granulocyte-
macrophage colony-stimulating factor; HUVEC, human umbilical vein endothe-
lial cell; mAb, monoclonal antibody; M-CSF, macrophage-colony-stimulating fac-
tor; M-CSFR, M-CSF receptor; Mgl2, macrophage galactose-type C-type lectin-2;
MMP9, matrix metalloproteinase 9; MMR, macrophage mannose receptor; MO-
MDSC, monocytic myeloid-derived suppressor cells; PAMP, pathogen-associated
molecular pattern; PMN-MDSC, polymorphonuclear myeloid-derived suppressor
cells; PyMT, polyomavirus middle T oncogene; RNI, reactive nitrogen intermediates;
ROS, reactive oxygen species; RT2, RIP1-Tag2; SR-A, scavenger receptor-A; TAM,
tumor-associated macrophages; TEM, Tie2-expressing monocytes/macrophages;
TGF-β, transforming growth factor-β; TIL, tumor-infiltrating lymphocytes; TIM,
tumor-infiltrating myeloid cells; TMEM, tumor microenvironment of metastasis;
VEGF, vascular endothelial growth factor.
energy metabolism, the capacity to evade elimination by the
immune system, including active immune suppression, as well as
smoldering, non-resolving inflammation, leading to accumulation
of random genetic alterations in cancer cells due to inflammatory
mediators, have been established as additional hallmarks of can-
cer (2–6). In this regard, tumors consist not only of neoplastic
cells, but should be considered as organ-like structures in which
a complex bidirectional interplay exists between transformed and
non-transformed cells. The malignant potential of transformed
cells requires an apt support structure from the stroma, which can
consist of fibroblasts, adipocytes, blood, and lymph vessels, but
may also be considerably infiltrated by a wide range of immune
cells, such as tumor-associated macrophages (TAM) (7).
PRO- AND ANTI-TUMORAL ROLES OF TAM
Tumor-associated macrophages are the predominant leukocytes
infiltrating solid tumors and can represent up to 50% of the
tumor mass. The clinical significance of these cells is illustrated
by the significant link between TAM number and density and a
poor prognosis in 80% of the reported studies. The main excep-
tion to this general trend seems to be colorectal cancer, for which a
high TAM density is significantly associated with enhanced overall
survival (8–10).
Tumor-associated macrophages stimulated by TLR ligands,
agonistic anti-CD40, or IFN-γ were shown to have important
anti-tumoral activities, provided that cancer cell phagocytosis is
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not inhibited by CD47 expression on the malignant cells, which
is a “don’t-eat me signal” (11, 12). In addition, pro-inflammatory
macrophages are able to eliminate cancer cells via the production
of reactive oxygen species (ROS) and reactive nitrogen intermedi-
ates (RNI) and secrete chemokines that recruit and prime T cells
toward an anti-tumor phenotype in some cancer types, resulting
in retarded tumor growth or tumor regression (13–17).
Whereas TAM can exert anti-tumoral activities, the ambigu-
ous role of macrophages in tumor progression is reflected in the
finding that TAM can also actively contribute to each stage of can-
cer development and progression (Figure 1A). They can promote
cancer cell proliferation, invasion, metastasis, and angiogenesis by
releasing cytokines, growth factors, extracellular matrix-degrading
enzymes, and angiogenic factors including vascular endothelial
growth factor (VEGF), prokineticin (Bv8), and matrix metallopro-
teinase 9 (MMP9). TAM also inhibit cytotoxic T-cell activity by the
secretion of suppressive cytokines such as IL-10 and transforming
growth factor-β (TGF-β), high levels of arginase activity, and the
production of ROS or RNI (18–22). Finally, TAM contribute to
tumor relapse following tumor irradiation and anti-angiogenic
therapy (23).
It seems unlikely that the diverse anti-tumoral and tumor-
promoting activities of TAM are performed by a single cell type,
and the existence of distinct TAM subpopulations, linked to differ-
ent intratumoral microenvironments, has been predicted (10, 24).
Depending on the cancer type, the stage of tumor progression and
location within the tumor tissue, molecularly and functionally dis-
tinct TAM subpopulations coexist in tumors (25–27). This TAM
heterogeneity likely reflects the inherent plasticity of macrophages
in response to (micro-)environmental triggers.
MACROPHAGE PLASTICITY
Macrophages have a remarkable plasticity and are found in all
tissues, where they display great anatomical and functional diver-
sity. They are implicated in a spectrum of roles required for tissue
homeostasis, ranging from host defense against infectious agents,
to tissue development, wound healing, and immune regulation.
Accordingly, macrophages are able to adopt diverse phenotypes
or activation states in response to environmental cues, such as
cytokines, pathogen-associated molecular patterns (PAMP), tis-
sue damage-associated molecular patterns (DAMP), and other
immune stimuli (7, 28, 29).
Macrophage activation is conventionally categorized on a lin-
ear scale, in which the two opposing phenotypes are referred to
as the classical (M1) versus alternative (M2) macrophage activa-
tion state, originally mirroring the Th1 versus Th2 nomenclature
(30–34). M1 macrophage activation is driven by exposure to IFN-
γ and TLR ligands. These macrophages secrete pro-inflammatory
cytokines (such as IL-12, IL-1, IL-6, TNF, ROS, RNI), promote Th1
responses, exert cytotoxic activities, and are involved in defense
against bacterial infections and intracellular pathogens. The M2
activation state refers to macrophages that are not M1 activated
and comprise various activation states, induced by a wide array
of different stimuli, leading to different macrophage classification
systems by different authors. These stimuli include Th2 cytokines
(such as IL-4 and IL-13), anti-inflammatory cytokines (such as IL-
10 and TGF-β), hormones (such as glucocorticoids), and immune
complexes. Consequently, non-M1 macrophages have very diverse
functions, ranging from parasite control to immune suppression,
wound repair, tissue remodeling, and angiogenesis. Features of
these non-M1 macrophages are the low secretion levels of pro-
inflammatory cytokines, high expression of macrophage mannose
receptor (MMR) and scavenger receptor-A (SR-A), and an argi-
nine metabolism shifted toward the production of ornithine and
polyamines by arginase (35–39). Although the M1/M2 classifi-
cation has proven useful, any form of classification underscores
the complexity of the in vivo situation, in which numerous stimuli
interact to define the final differentiated state and mixed functional
profile of macrophages (40–42). In this context, new nomencla-
ture and experimental guidelines for dealing with macrophage
activation and polarization have very recently been proposed (43).
M-CSF AS DRIVER OF BOTH DIFFERENTIATION AND PHENOTYPIC
POLARIZATION OF MACROPHAGES
The myelopoietic growth factors macrophage-colony-stimulating
factor (M-CSF, also known as CSF-1), granulocyte-macrophage-
colony-stimulating factor (GM-CSF) and IL-34 are major
cytokines in controlling the proliferation, differentiation, and
functional regulation of monocytes, macrophages, and dendritic
cells [reviewed in Ref. (44)]. M-CSF and IL-34 are produced by
a variety of stromal and epithelial cell types and signal through
the M-CSF receptor (M-CSFR, CSF-1R, or CD115), a type III
receptor tyrosine kinase (45), encoded by the Csf1r/c-fms proto-
oncogene (46, 47), that seems to be mainly restricted to cells of the
mononuclear phagocyte lineage (48).
Especially, M-CSF instructs the myeloid fate in single
hematopoietic stem cells, by inducing the myeloid master regu-
lator transcription factor PU.1 (49). Embryonic yolk sac-derived
precursors and fetal liver monocytes have been found to give rise to
many tissue-resident macrophages that seed all tissues prenatally
and are maintained via self-renewal throughout adult life (50). The
importance of M-CSF for establishing and maintaining the tissue-
resident macrophage pool is illustrated by the M-CSF-deficient
osteopetrotic (op/op) mouse, which not only suffers from con-
genital osteopetrosis due to a severe deficiency of osteoclasts, but
also features severe defects in many tissue-resident macrophage
populations (51). Besides having effects on macrophage precursor
differentiation, M-CSF is known to stimulate macrophage sur-
vival (52) and self-renewal during steady-state and inflammation
(53). However, macrophage populations in distinct tissues are dif-
ferentially affected by the M-CSF deficiency. For example, skin
Langerhans cells and brain microglia were seemingly normal in
op/op mice, but were largely absent from M-CSFR-deficient mice,
a finding which has been explained by the trophic role of IL-34,
whose production is restricted to keratinocytes and neurons under
steady-state (54, 55).
In addition to a role in resident tissue macrophage differ-
entiation and maintenance, M-CSFR signaling has also been
assigned an important role in polarization of macrophage acti-
vation, flowing from the observation of significant differences
in the transcriptomes of the macrophage populations primar-
ily generated with the use of M-CSF or GM-CSF. M-CSF-driven
macrophage differentiation leads to the expression of a substan-
tial part of the M2 transcriptome, including expression of MMR
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FIGURE 1 | Scheme of the possible effects ofTAM and of M-CSFR
blockade on cancer progression. (A) Possible tumor-promoting effects of
TAM. TAM can promote cancer progression and reduce the efficacy of
radiotherapy, chemotherapy, immunotherapy, and anti-angiogenic therapy by a
combination of different mechanisms. TAM can contribute to enhanced
cancer cell numbers by (Aa) inhibiting anti-tumor immune responses and via
(Ab) stimulation/maintenance of cancer cell proliferation. TAM can also exert
pro-angiogenic activities by enhancing (Ac) angiogenic switching and (Ad)
endothelial cell proliferation. Finally, TAM can contribute to cancer malignancy
by facilitating (Ae) cancer cell invasion and (Af) seeding, extravasation,
survival, and subsequent proliferation of cancer cells at metastatic sites.
(B) Possible effects of M-CSFR signaling blockade on cancer progression.
Depending on the tumor type/model and the blocking agents used to impede
M-CSFR signaling, M-CSFR blockade has in most cases been reported to
attenuate cancer progression and/or synergistically enhance the effect of
chemo-, radio-, and/or immunotherapy via various effects, including (Ba)
promotion of tumor-infiltrating lymphocytes (TIL) recruitment and/or
activation, (Bb) enhanced phagocytosis/killing of cancer cells, (Bc) a delayed
angiogenic switch, (Bd) reduced density of proliferating endothelial cells, (Be)
inhibition of both TAM and cancer cell migration and invasion, (Bf) reduced
metastasis. In some cases, (Bg) reduction of tumor weight and primary tumor
growth has been reported. A number of studies have attributed these effects
to (i) ablation of TAM numbers and/or (ii) phenotypic reprograming of TAM
from tumor promoting (often M2-like) TAM to anti-tumor (often M1-like) TAM.
and SR-A, while GM-CSF rather induces a pro-inflammatory
M1-type of activation (49, 56–58). As such, blocking M-CSFR
signaling in myometrial macrophages stimulated the occurrence
of an M1-like MHC-IIhigh population at the expense of M2-
like MHC-IIlow macrophages in the pregnant mouse uterus (59).
The same study also demonstrated an important role for M-CSF
in mediating monocyte extravasation to the tissue, via M-CSF-
dependent upregulation of the chemokine CCL2, adding further
evidence to the notion that M-CSF affects macrophage dynamics
at multiple levels.
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Since high M-CSF levels are frequently found in tumor-bearing
hosts, the M-CSFR signaling could also play a role in shaping the
TAM pool and regulating their activation state.
ASSOCIATION OF M-CSF AND M-CSFR LEVELS WITH
HUMAN CANCER PROGRESSION
M-CSF, M-CSFR, AND/OR M-CSF RESPONSE SIGNATURE EXPRESSION
IN TUMOR TISSUE
Various studies have documented analyses in which attempts were
made to correlate clinical cancer patient parameters such as disease
staging and survival with protein and/or mRNA expression levels
of M-CSF, M-CSFR, and/or M-CSF response genes. The latter were
thereby in turn considered to correlate with the presence of high
levels of TAM and thus to represent a macrophage signature.
High M-CSF expression levels, as detected via IHC on tissue
sections, have been reported to associate with higher histologi-
cal tumor grading and in many cases also with more frequent
metastases and poor prognosis in various cancer types, includ-
ing breast cancer (60), serous and mucinous ovarian epithe-
lial tumors (61), endometrioid carcinomas (62), and papillary
renal cell carcinoma (63). In gynecological and non-gynecological
leiomyosarcoma, expression of individual markers such as M-
CSF was found to show at least a trend for correlation with
poor outcome, but only the co-expression of M-CSF and three
M-CSF-response genes (CTSL1, FCGR3a, and CD163) was inde-
pendently associated with a worse survival in a multivariate
analysis (64).
Studying the expression of M-CSFR via IHC in a large cohort of
clinical breast cancer specimens using tissue microarrays revealed
that M-CSFR expression was strongly associated with nodal status
(65). In fact, in multivariate analysis, M-CSFR was not indepen-
dent of nodal status as a predictor of survival. The study also
revealed that M-CSFR expression was associated with decreased
overall survival in non-metastatic breast cancer patients, but not
in node-positive patients (65). Of note, in a recent manuscript, low
levels of the M-CSFR gene were reported to predict worse overall
survival based on online survival analysis tools allowing an evalua-
tion of the prognostic value of genes in breast cancer patients using
microarray data (66). In another recent study, a high number of
tumor stromal cells – but not the cancer cells themselves – express-
ing M-CSFR was found to be an independent prognostic marker
for lower event free survival and lower overall survival in classical
Hodgkin lymphoma (67).
In line with variable results on association of M-CSFR expres-
sion with overall survival among different cancer types and patient
groups, one report of a study using gene microarray and tissue
microarray analyses for evaluating the prognostic value of an M-
CSF response signature in breast cancer patients, mentioned a
complex relationship of the signature with survival. Indeed, when
patients were substratified in subsets, the M-CSF response signa-
ture was associated with poor prognosis among low-grade tumors
and showed a trend for an association with improved progno-
sis among estrogen-receptor-negative tumors and among tumors
with a TP53 mutation gene-expression signature (68). This vari-
ability in the association of M-CSF/macrophage signatures with
clinical parameters points to the need to properly identify patient
groups in which an M-CSF/macrophage signature correlates with
worse prognosis and which are thus most likely to benefit from
M-CSF/macrophage-targeted therapies.
It should also be remarked that the presence of an M-
CSF/macrophage signature is not a uniform feature in all cancer
patients. In fact, gene microarray and tissue microarray analyses
revealed M-CSF and M-CSF response signature genes to be present
in 17–25% of breast cancers (68) and in about 27% of myoinvasive
endometrioid carcinomas (62). Yet, in the latter case, concor-
dance between the expression of the M-CSF signature in primary
endometrioid carcinomas and in their corresponding lymph node
metastases was reported. Moreover, in case of breast carcinoma,
expression of the M-CSF signature was not only detected in some
patients in case of invasive ductal carcinoma, but was already
detected at the stage of ductal carcinoma in situ. Also in that case,
a correlation was found between the presence of the M-CSF signa-
ture in ductal carcinoma in situ and in invasive ductal carcinoma
within the same patient (69). This conservation of the expression
of the M-CSF signatures upon disease progression is promising
when considering targeting of the M-CSF pathway as a therapeutic
option for invasive and/or metastatic disease, and suggests that the
presence of a M-CSF/macrophage signature in the primary tumor
may be useful for patient stratification to identify those patients
who are most likely to respond to M-CSF/macrophage-targeted
therapies.
CIRCULATING M-CSF
In some cases, M-CSF is produced to such high levels in cancer
patients that it can be detected systemically. Overall trends from
studies in patients with newly diagnosed breast tumors indicate
that circulating plasma M-CSF levels are not higher in patients
with localized tumors than in controls, but are elevated in patients
with regionally advanced disease and distant metastases (70, 71).
Median M-CSF levels were also reported to be dramatically higher
in patients with newly diagnosed tumors of the head and neck,
in men with prostate cancer metastatic to bone and women with
advanced metastatic breast cancer than those seen in patients with
newly diagnosed breast tumors (70).
Prospective studies of the prognostic value of serum M-CSF
levels have yielded conflicting results. One study on 471 women
with pre-invasive and invasive breast carcinoma reported no sig-
nificant association between pre-treatment plasma levels of M-
CSF and overall/relapse free survival at a median follow up of
5.6 years. In this study, patients were classified into three groups
based on the level of initial M-CSF, using median and twice median
plasma values as cut-off points (70). In contrast, a recent study
of 572 women with early breast cancer, that had not undergone
local or systemic anti-cancer treatment prior to serum collection,
revealed significantly poorer outcome at a median follow-up of
5.2 years in patients with above-median M-CSF concentrations as
compared to those with below-median M-CSF concentrations.
In this study population, log M-CSF serum concentrations at
study enrollment were predictive of poor survival in both uni-
variate analysis, as well as multivariate analysis adjusted for age,
tumor size, nodal status, and tumor grade (71). In a retrospec-
tive, nested case–control study of breast cancer risk in 726 breast
cancer patients and 734 matched controls with no cancer his-
tory, the association of circulating M-CSF levels with the risk of
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developing breast cancer was found to vary by menopausal sta-
tus. High M-CSF levels were associated with a reduced risk of
premenopausal breast cancer, whereas they were associated with
an increased risk of postmenopausal breast cancer (72). Interest-
ingly, in the aforementioned prospective study, the reported poorer
outcome in patients with above-median M-CSF concentrations
was confined to postmenopausal women, while no such effect was
observed in premenopausal women with early breast cancer (71).
Overall, although the practical use of serum M-CSF levels as
prognostic factor for cancer risk and/or outcome may be compli-
cated by a high heterogeneity among patient groups and difficulties
in determining optimal cut-off levels for plasma M-CSF, these
results do suggest that, at least in some patient groups, M-CSF
and M-CSF-dependent macrophages may be directly involved in
tumor progression and malignant behavior and thus constitute
interesting therapeutic targets.
TAM PHENOTYPIC AND SUBPOPULATION HETEROGENEITY
Originally, TAM were characterized as M2-like cells, proficient in
inducing trophic functions like tumor angiogenesis, invasion, pro-
liferation, and expressing the anti-inflammatory cytokine IL-10.
These cells were also reported to express M2-specific markers like
arginase-1, macrophage galactose-type C-type lectin-2 (Mgl2),
found in inflammatory zone 1 (Fizz1), Ym1, TGF-β, SR-A, and
MMR (73–76). However, some studies of chronic inflammation-
induced cancer indicate the presence of TAM with an inflam-
matory M1-like phenotype, releasing inflammatory cytokines like
IL-12, TNF, IL-6, and IL-1, or with overlapping M1 and M2
characteristics (77–79).
A dynamic switch in the phenotype of TAM during tumor
progression might account for the mixed activation state of TAM
subsets found in different established tumors. Indeed, in some
models, tumor progression is associated with a switch from M1-
like to M2-like TAM (80, 81). Hence, M2-like TAM can be linked
to tumor promotion and their presence is indicative of poor
prognosis (82, 83). Accordingly, a high M1/M2 TAM ratio has
been associated with extended survival in many cancer types (84).
Moreover, inhibition of monocyte differentiation to M2-like TAM
through inhibition of NF-κB signaling, results in an M1-like phe-
notype and reduced tumor growth (85). Hence, a picture emerges
whereby M2-like TAM are pro-tumoral, and M1-like TAM exert
anti-tumoral activities.
Accumulating evidence suggests that different TAM activa-
tion states found within the same tumor may reflect responses
to divergent local microenvionmental signals (86). As previ-
ously mentioned, tumors are complex organoid structures con-
taining peritumoral stroma, perivascular regions, and hypoxic
regions, which can all be populated by TAM, albeit with a dif-
ferent molecular profile and exerting specialized functions (86–
89). Different studies, using state-of-the-art microscopy, clearly
illustrated the existence of at least two distinct microenviron-
ments in the same tumor, which were both infiltrated by TAM
subsets. TAM residing in avascular regions are sessile, have a
high phagocytic capacity, and express high levels of many pro-
totypical M2 markers such as MMR. In contrast, perivascular
TAM are migratory, are not able to ingest dextran, have a less
pronounced M2-profile and produce epidermal growth factor
(EGF), which attracts M-CSF-producing cancer cells, resulting
in migration and intravasation of cancer cells (90–94). In line
with these findings, differentially activated macrophages within
the same tumors, residing in distinctively oxygenated tumor
regions, could be discriminated based on the expression of MHC-
II. MHC-IIhigh TAM are excluded from hypoxic avascular areas
and more M1 oriented, while hypoxic MHC-IIlow TAM express
higher levels of M2-associated markers and are more angiogenic
(25–27, 95). However, increasing the oxygenation of neoplastic
lesions by vessel normalization in PHD2-haplodeficient mice was
recently found not to alter the expression of the most promi-
nent M2 markers, such as MMR, IL-4Rα, and Arginase-1. Rather,
reduced hypoxia down-regulated a subset of genes and proteins
involved in glycolysis, angiogenesis, and metastasis, thereby low-
ering their angiogenic functions, specifically and solely in the
hypoxic MHC-IIlow TAM subset (27). Hence, hypoxia is not the
main driver of TAM differentiation, but M2-like TAM prefer-
entially home to hypoxic areas where the pro-tumoral activities
of these cells are promoted. The importance of the intratu-
moral TAM location in shaping the phenotype of TAM sub-
populations was further confirmed by a study showing that
Neuropilin-1 deficiency in macrophages prohibits their migra-
tion to hypoxic tumor areas, resulting in an increased inflam-
matory phenotype and the initiation of an anti-tumor immune
response (96).
EFFECTS OF M-CSFR SIGNALING ON NUMBERS AND
PHENOTYPE OF TAM AND OTHER TIM
The critical role of M-CSF in the turn-over of TAM is reflected
in the drastic reduction in macrophages in the primary tumor
at different stages of tumor progression to malignancy that
has been observed in the absence of M-CSF in osteopetrotic
op/op mice (97, 98). Conversely, restoration of M-CSF sig-
naling via transgenic expression of M-CSF in the mammary
epithelium led to enhanced numbers of macrophages in pri-
mary mammary tumors (97). Similarly, strong reductions in
the number of TAM have been reported in various tumor
models upon blocking of M-CSF/M-CSFR signaling to TAM
using either blocking monoclonal antibodies (mAbs) target-
ing M-CSF (66, 99) or the extracellular domain of M-CSFR
(100–102) or small molecule inhibitors of the M-CSFR tyro-
sine kinase activity in order to block the downstream signaling
(102–105) (Figure 2).
Despite numerous reports of the differential effects of M-CSF
versus GM-CSF on macrophage polarization (44, 57), only few
studies directly addressing the effect of M-CSFR blockade on the
M1/M2 activation state and/or subpopulation heterogeneity of
TAM have recently been documented (Table 1).
One study in a mouse model based on subcutaneously inoc-
ulated colon carcinoma cells was aimed at evaluating whether
cytokine signaling could induce reprograming of the TAM phe-
notype in vitro. The authors reported that GM-CSF treatment
in conjunction with suppression of M-CSF signals using siRNA
against the M-CSFR resulted in an altered signal transduction
pathway of TAM, whereby expression of STAT1, STAT5, and STAT6
was increased. In this study, treatment of TAM with GM-CSF,
alone, or in conjunction with suppression of M-CSFR signals,
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FIGURE 2 | Examples of various types of M-CSFR signaling blocking
agents mentioned throughout this manuscript. In some studies,
neutralizing anti-mouse M-CSF mAb has been used for blocking
M-CSF/M-CSFR signaling (66). One study also reported on the use of a
murinized, polyethylene glycol-linked recombinant Fab fragment of the
MCSF1-033 neutralizing rabbit anti-mouse M-CSF antibody (99). Yet,
blocking mAbs targeting the extracellular domains of the M-CSFR have
more frequently been documented for blocking the M-CSF/M-CSFR
signaling axis. Typical examples of the latter that have been used in mouse
tumor models are the rat IgG1 M279 (100) and the rat IgG2A AFS98 (101,
102). A recent report documented the generation of RG7155, a humanized
anti-human M-CSFR IgG1 mAb that inhibits M-CSFR activation (106). And
also the fully human IgG1 anti-human M-CSFR mAb IMC-CS4 is currently in
clinical trials (107). M-CSFR signaling has also been inhibited via
pharmacological, small molecule inhibitors targeting the intracellular
catalytic domains of the receptor involved in signal transduction. A number
of these tyrosine kinase inhibitors, such as CYC11645, Ki20227, GW2580, or
BLZ945, have been screened for highly selective inhibition of M-CSFR
signaling, very potent IC50 values for M-CSFR and at least a 100-fold lower
inhibitory activity for other tested receptor tyrosine kinases (66, 108–110).
Also the PLX3397 tyrosine kinase inhibitor has been used, which has higher
M-CSFR inhibitory activity as compared to GW2580, but which is less
specific since it inhibits the c-Kit receptor tyrosine kinase with similar
potency as the M-CSFR tyrosine kinase (105). In one study, the actual
contribution of M-CSFR blockade in the effect of PLX3397 has been
assessed by comparing it with the specific cKit tyrosine kinase inhibitor
imatinib and PLX5622, an M-CSFR-specific inhibitor of equal potency to
PLX3397 that does not appreciably inhibit Kit (111).
did not alter the TAM expression pattern of M1/M2 marker
molecules (112).
In a study, whereby the tyrosine kinase inhibitor PLX3397
was used as a combination treatment with adoptive cell ther-
apy of melanoma-targeted T cells in a syngeneic mouse model
of BRAFV600E-driven melanoma, PLX3397 as single or combi-
nation treatment resulted in a dramatic reduction of TAM and
a skewing of the subpopulation balance in the remaining TAM
from predominant M2-oriented MHC-IIlow to predominant M1-
oriented MHC-IIhigh macrophages (113). A similar shift in the
relative amount of TAM subpopulations was documented in the
transgenic mouse MMTV-Neu model, in which mammary car-
cinogenesis is driven by the mammary epithelial restricted expres-
sion of the ErbB2/Neu oncogene. Blocking M-CSFR in this model
by using the M-CSFR inhibitor GW2580, led to a significant
reduction in the amount of M2-like F4/80high TAM, which had
moderate levels of MHC-II, and not in the MHC-IIhigh F4/80low
TAM, elucidating a role for M-CSFR signaling in the mainte-
nance or expansion of the M2-like TAM subset (95). A recent
study in a mouse model of pancreatic ductal adenocarcinoma
confirmed this notion. In this model, treatment with PLX3397 or
a neutralizing anti-M-CSF mAb resulted in a drastic reduction
in TAM (114). Thereby, the authors demonstrated that block-
ing M-CSF/M-CSFR signaling resulted in preferential depletion
of M2-like MMRhigh TAM, whereas M1-like MMRlow TAM were
much less affected. The observation that the MMRhigh TAM subset
had significantly higher M-CSFR expression levels as compared to
the MMRlow TAM subset further supports the notion that these
M2-like cells may be more dependent on the M-CSF signal. As a
consequence, the gene-expression profile of TAM upon M-CSFR
signaling blockade featured a reduced expression of M2 mark-
ers and an increased expression of M1 markers and MHC-II. In
parallel, the TAM phenotype shifted from predominant immuno-
suppressive properties to improved antigen presentation capacity
(114). In a mouse glioblastoma model, in vivo M-CSFR inhibition
using the small molecule M-CSFR inhibitor BLZ945 was reported
not to result in TAM depletion. Instead, glioma-secreted factors,
including GM-CSF and IFN-γ, facilitated TAM survival in the
Frontiers in Immunology | Molecular Innate Immunity October 2014 | Volume 5 | Article 489 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Laoui et al. TAM and M-CSF in cancer progression
Table 1 | Documented effects of M-CSFR inhibition onTAM abundance and activation state.
Mouse tumor
model
Tool used to inhibit
M-CSFR signaling
Amount ofTAM TAM M1/M2 activation
state
Effect/outcome Reference
Colon carcinoma In vitro: siRNA against
M-CSFR+GM-CSF
Unaltered Unaltered Increased expression of STAT1,
STAT5, STAT6 in TAM
(112)
Melanoma M-CSFR inhibitor:
PLX3397+ adoptive
cell therapy
Reduced Skewing from M2
MHC-IIlow to M1
MHC-IIhigh
Improved adoptive cell therapy:
increased amount and activation
of tumor-infiltrating lymphocytes;
reduced tumor growth
(113)
Mammary carcinoma M-CSFR inhibitor:
GW2580
Reduced (only M2-like
MHC-IIlow TAM)
Not assessed Role of M-CSFR in maintenance
of M2-like TAM
(95)
Pancreatic ductal
adenocarcinoma
M-CSFR inhibitor:
PLX3397/neutralizing
α-M-CSF MAb
Reduced (mainly M2-like
MMRhigh TAM)
Remaining TAM are less
immunosuppressive,
better Ag presenting M1
Increased anti-tumor T cell
activity; enhanced response to
immunotherapy
(114)
Glioblastoma M-CSFR inhibitor:
BLZ945
Unaltered Repolarization from
pro-tumoral M2 to
phagocytic M1 TAM
Reduced tumor growth (108)
Cervical and
mammary carcinoma
M-CSFR inhibitor:
BLZ945
Reduced (both MHC-IIlow
and MHC-IIhigh TAM)
Not assessed Increased amount of CD8+ T
cells; reduced tumor growth
(104)
Pancreatic ductal
adenocarcinoma
M-CSFR inhibitor:
PLX3397 or GW2580
Reduced (mainly M1-like
immunosuppressive
MHC-IIhigh TAM)
Remaining TAM are less
immunosuppressive
Enhanced response to
chemotherapy; increased CTL
response; reduced metastases
(105)
context of M-CSFR inhibition and resulted in a repolarization
from pro-tumoral M2 to a highly phagocytic M1 phenotype, with
a decreased expression of M2 markers (108).
Despite the above examples indicating that M-CSFR block-
ade can shift the balance in TAM subpopulations from tumor-
promoting M2-oriented MHC-IIlow or MMRhigh to anti-tumoral
M1-oriented MHC-IIhigh or MMRlow macrophages, conflicting
reports also exist. For example, the M-CSFR inhibitor BLZ945
was reported to result in a decrease in the level of TAM in cervical
and breast carcinomas by attenuating their turn-over rate. Hereby,
similar kinetics of depletion and recovery were observed for both
MHC-IIlow and MHC-IIhigh TAM subpopulations (104). And in
mice bearing transplantable pancreatic ductal adenocarcinomas,
the M-CSFR inhibitors GW2580 or PLX3397 were even reported to
significantly deplete macrophages expressing high levels of MHC-
II, but not the more M2-oriented MHC-IIlow or Tie2+ TAM (105).
Yet, in the latter case and in contrast to the examples above, the
MHC-IIhigh TAM were found to constitute the predominant TAM
subpopulation and to exert pro-tumoral activities by suppress-
ing anti-tumoral CD8+ T cell responses (105). Therefore, also in
that case, the observed reduction in the level of the predominant
tumor-promoting TAM subpopulation, occurring upon M-CSFR
blockade, resulted in attenuation of cancer malignancy (Table 1).
Further studies will be required to obtain better insights into the
extent and the underlying mechanisms by which M-CSFR signal-
ing and blockade thereof can contribute to shaping the phenotypic
and subpopulation heterogeneity of TAM, thereby re-educating
TAM toward anti-tumoral effector populations, thus contributing
to combating disease progression. It will also be of importance to
assess to what extent the remaining TAM populations detected
after M-CSFR signaling blockade in various cancer types and
tumor models are actually M-CSF-dependent macrophages for
which the depletion was incomplete or the M-CSF dependence
has been (partially) compensated for by other factors. Or do these
remaining cells in some instances represent M-CSF-independent
cells with a distinct lineage origin (such as for example cer-
tain dendritic cell types) for which the lineage surface markers
and morphological analysis used in the current studies have not
allowed to discriminate them from macrophages?
Of note, a number of recent publications evaluat-
ing the effect of M-CSFR inhibitors such as GW2580
or PLX3397 on various populations of tumor-infiltrating
myeloid cells (TIM) have documented a reduction of not
only mature CD11b+Ly6G-Ly6ClowF4/80high TAM, but also of
CD11b+Ly6G-Ly6ChighF4/80mid cells, resembling the surface
receptor phenotype and morphology of inflammatory (classical)
monocytes or monocytic myeloid-derived suppressor cells (MO-
MDSC) (105, 114–116). Taking into account the diversity of cell
populations that can express these combinations of surface mark-
ers and the fact that an actual suppressive activity of the cells
has not been demonstrated by the authors of most of these stud-
ies, we will term these cells MO-MDSC-like cells in the current
review. It makes sense that, as monocyte-lineage cells, these tumor-
infiltrating MO-MDSC-like cells are dependent on M-CSFR sig-
naling to a similar extent as mature TAM and these MO-MDSC-
like cells may in fact very well represent precursors of mature TAM
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(117). In contrast to MO-MDSC-like cells, documented effects
of M-CSFR signaling inhibitors on CD11b+Ly6GhighLy6Clow
cells, resembling the surface receptor phenotype and morphol-
ogy of immature granulocytes/neutrophils or polymorphonuclear
myeloid-derived suppressor cells (PMN-MDSC) and which we
will term PMN-MDSC-like cells have been more variable. Most
studies revealed no reduction (and sometimes even a limited
increase) in the number of PMN-MDSC-like cells in response
to PLX3397 or GW2580 treatment, for example in mice bearing
murine pancreatic ductal adenocarcinoma (105, 114) or in the 3LL
lung carcinoma model (115). In contrast, PLX3397 was found to
reduce both MO-MDSC-like cells and PMN-MDSC-like cells in
one study in the RM-1 and Myc-CaP prostate cancer models (116).
The variable effect of M-CSFR blockade on PMN-MDSC-like cells
suggests that this effect is most likely indirect and may depend on
other (growth) factors in the tumor microenvironment that are
affected indirectly via the M-CSFR blocking.
EFFECTS OF M-CSFR SIGNALING BLOCKADE ON CANCER
PROGRESSION AND THE ROLE OF TAM THEREIN
Depending on the tumor type/model and the blocking agents used
to impede M-CSFR signaling (Figure 2) (variable) effects of M-
CSFR blockade on different aspects of cancer progression have
been reported (Figure 1B).
EFFECTS ON TUMOR INCIDENCE AND PRIMARY TUMOR GROWTH
To assess the role of M-CSF in tumor development and pro-
gression, csf1op/op mice have been crossed with transgenic mice
in which mammary tumors develop due to mammary epithe-
lial restricted expression of the Polyomavirus middle T oncogene
(PyMT). In these experiments, the drastic reduction in TAM num-
bers in the absence of M-CSF was reported neither to affect the
incidence nor the growth of the primary tumors but rather to delay
their development to invasive, metastatic carcinomas (97). In fact,
the PyMT model is characterized by the development of a single
primary tumor focus on the ducts emanating from the nipple,
after which other tumors arise in the ducts distant to the nipple.
Although the development of multiple foci on the distal ducts was
reduced in the csf1op/op PyMT mammary glands, the growth rate
of the primary tumor size and the proliferation rate of the cancer
cells were comparable to those in M-CSF sufficient mice.
Similarly, treatment of AE5MG mesothelioma or LLC lung car-
cinoma bearing mice with the M-CSFR blocking mAb M279 was
described not to result in a significant effect on tumor growth
or final tumor burden, despite a strong reduction in the num-
ber of TAM (100). In contrast, publications reporting on the
use of another mAb, AFS98, for M-CSFR blockade and ensuing
TAM inhibition, documented inhibition of primary tumor growth
in different mouse tumor models including the implanted AX
osteosarcoma model (102) and later also in the EL4 transplanted
lymphoma model, the PyMT transgenic breast carcinoma model
and the MDA-MB231 breast cancer metastasis-induced osteoly-
sis model (101). It has been suggested that the effect of the rat
IgG1 M279 may represent the biological response to blocking
CSF-1R signaling per se, whereas the isotype of the rat IgG2A
AFS98 may result in additional effector functions such as direct
macrophage depletion upon recognition by and/or aggregation
with other macrophages through binding of the IgG2A antibody to
the high affinity IgG receptor CD64 on mouse macrophages (52).
In human, MCF-7 mammary carcinoma cell xenografts in
immunodeficient mice, M-CSF blockade by antisense oligonu-
cleotides and small interfering RNAs has been shown to reduce
host macrophage infiltration and suppress tumor growth (118).
Concerning the effect of pharmacologic M-CSFR blockade on
primary tumor growth, the M-CSFR tyrosine kinase inhibitor
Ki20227 was described to reduce TAM content of tumors and
retard tumor cell proliferation in osteosarcoma (102) and simi-
lar results were reported for GW2580 in papillary thyroid cancer
(103). Yet, the reduction in intratumoral proliferation in GW2580-
treated papillary thyroid cancers was most evident within the stro-
mal compartment (103). These results suggest that the observed
effects of M-CSF blockade may in that case at least partially reflect
inhibition of stromal cells such as TAM rather than cancer cell
proliferation per se. In murine prostate cancer models, the M-
CSFR inhibitors GW2580 or PLX3397 as a single treatment were
reported to have little effect on tumor growth compared with the
control group, despite effective TAM ablation.
A recent study clearly illustrates that the specificity of the
applied inhibitors for M-CSF as compared to other tyrosine
kinases and the relative contribution of the effect on TAM as
compared to direct effects on the cancer cells should be care-
fully considered when interpreting the effect of M-CSFR block-
ers on tumor growth. In this study, PLX3397 was found to
result in effective reduction of tumor weight and cellularity in
both the KitV558del/+ transgenic murine gastrointestinal stromal
tumor (GAST) model and in human GAST xenografts (111).
These GAST cells are known to be strongly dependent on sig-
naling via the oncogene cKit for their survival and the growth
inhibitory effect of PLX3397 was even stronger than that of the
cKit tyrosine kinase inhibitor imatinib, correlating with a supe-
rior capacity of PLX3397 as compared to imatinib to decrease
the viability of two human GAST cell lines in vitro. On the
other hand, TAM were deleted to a much greater degree in mice
treated with PLX3397 than with imatinib, correlating with a more
potent M-CSFR inhibition by PLX3397 as compared to ima-
tinib. Therefore, one could hypothesize that the superior effect
of PLX3397 on tumor growth inhibition could at least in part
be related to superior inhibition of M-CSF signaling and conse-
quent TAM attenuation, acting synergistically to the Kit inhibi-
tion. To address this possibility, the authors combined imatinib
with PLX5622, an M-CSFR-specific inhibitor of equal potency
to PLX3397 that does not appreciably inhibit Kit. Despite com-
parable levels of TAM reduction as PLX3397 therapy, treatment
with PLX5622 did not enhance the effect of imatinib on tumor
weight, cell number, or histology, suggesting that inhibition of
cKit signaling but not M-CSFR signaling is the main factor deter-
mining the capacity of tyrosine kinase inhibitors for GAST growth
inhibition (111).
Overall, despite consistent reduction in TAM content in pri-
mary tumors in the various tumor models discussed above, the
effects of M-CSF or M-CSFR blockade and consequent TAM
attenuation on primary tumor growth seem to be quite variable,
depending on the tumor model and the blocking agents used, and
thus do not seem to correlate with TAM depletion per se.
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EFFECTS ON TUMOR ANGIOGENESIS
Crossing PyMT and csf1op/op mice revealed that a low density of
macrophages in the primary tumors correlated with a delay in the
angiogenic switch, identified as the formation of a high-density
vessel network. Genetic restoration of macrophage numbers in
the tumors of these mice by the transgenic expression of M-
CSF specifically in the mammary epithelium thereby rescued the
vessel phenotype (119). Similarly, crossing csf1op/op mice to the
RIP1-Tag2 (RT2) mouse model of pancreatic islet cancer was doc-
umented to decrease TAM by approximately 50% during all stages
of RT2 tumor progression and to generate a substantial reduction
in cumulative tumor burden, which resulted from a significant
decrease in angiogenic switching and the number of tumors, rather
than an evident effect on the growth of established tumors or on
the cancer cell proliferative capacity (98).
In a mammary tumor model based on xenografts of human
MCF-7 breast cancer cells in athymic nude mice, mouse (host)
M-CSF expression was found to be induced as the tumors pro-
gressed. In these mice, treatment with a murinized, polyethylene
glycol-linked recombinant Fab fragment of the MCSF1-033 neu-
tralizing rabbit anti-mouse M-CSF antibody reduced the density
of both macrophages and proliferating endothelial cells, the latter
reflecting decreased levels of angiogenic activity in the mammary
tumor xenografts (99). In an immunocompetent mouse model of
osteosarcoma, in which mice were subcutaneously transplanted
with the mouse AX osteosarcoma cell line, the M-CSF inhibitor
Ki20227 or the AFS98 rat anti-murine M-CSFR mAb dramatically
decreased peritumoral and perivascular TAM, suppressed tumor
angiogenesis and lymphangiogenesis, disorganized extracellular
matrices and concomitantly dramatically suppressed metastasis
and improved prognosis (102). In contrast to VEGF blockade,
interruption of M-CSF signaling did not promote rapid vascular
regrowth. In addition, continuous M-CSF inhibition did not affect
healthy vascular and lymphatic systems outside tumors (102).
The notion that M-CSFR+ TIM, including both TAM and MO-
MDSC-like cells, contribute significantly to tumor angiogenesis,
was supported by Priceman et al. (115), showing that deple-
tion of M-CSF-dependent TAM and MO-MDSC-like cells in the
3LL lung carcinoma model, using either the M-CSFR inhibitor
GW2580 or a transgenic approach in chimeric mice, resulted
in significant reduction in angiogenesis in TIM-ablated tumors
(without a concomitant decrease in tumor growth). The authors
confirmed that, also in the orthotopic RM-1 prostate tumor model,
M-CSF blockade resulted in reduced levels of TAM, and MO-
MDSC-like cells, associated with reduced angiogenesis and, to a
lesser extent, lymphangiogenesis, as reflected by vessel density in
these tumors.
In the 3LL lung carcinoma model, GW2580 was in addi-
tion shown to attenuate tumor evasion of anti-angiogenic ther-
apy. In combination with DC101, a specific blocking antibody
against VEGFR-2, GW2580 resulted in greater inhibition of
tumor angiogenesis along with synergistic tumor growth reduc-
tion compared with anti-angiogenic therapy alone. In search for
a hypothesis on the mechanism underlying the reversal of anti-
angiogenesis in the combination therapy, the authors provided
histological data revealing more abundant MMP9 expressing cells
with heterogeneous myeloid cell morphology in viable areas of
DC101-treated tumors, which were reduced in the combination
group (115).
At a mechanistic level, M-CSF was also shown to induce VEGF
production in human monocytes through the MAPK/ERK path-
way via Sp1 and was reported to enhance angiogenesis in vivo, as
evidenced in an angiogenesis assay using an in vivo polymerized
MatrigelTM plug in mice (120). Recently, the mechanistic basis of
the tumor angiogenesis-promoting effect of M-CSF was further
expanded by showing that M-CSF augments differentiation of the
subpopulation of M2 macrophages expressing the endothelial cell
tyrosine kinase receptor, Tie2. Hereby, M-CSF-mediated upregu-
lation of Tie2 on these Tie2-expressing monocytes/macrophages
(TEM) increased branching of human umbilical vein endothe-
lial cells (HUVECs) in vitro and enhanced angiogenesis in
PyMT tumor-bearing mice. This M-CSF-stimulated Tie2 recep-
tor expression was found to be dependent on a synergistic
contribution from the PI3 kinase and HIF-1α pathways. (121).
As a final remark, it should be realized that high levels of angio-
genesis, driven by M2-like TAM, often lead to dysfunctional blood
vessels in tumors, resulting in more malignant cancer cells under
the influence of tumor hypoxia and an easy access of these cells to
the blood circulation. TAM depletion or the conversion of M2-like
TAM to M1-like TAM, thereby results in vessel normalization and
reduced metastasis (122). In addition, normalized vessels allow a
more efficient administration of therapeutic agents to the tumor
microenvironment.
EFFECTS ON CANCER CELL INVASION AND METASTASIS
Accumulating evidence in the first decade of this century has sup-
ported the tenet that delayed development of invasive, metastatic
carcinomas in PyMT csf1op/op mice is reflective of a role for M-CSF
in promoting cancer cell invasion by regulating the infiltration
and function of TAM. Indeed, at the PyMT tumor site, expres-
sion of M-CSFR was reported to be restricted to macrophages.
Moreover, restoration of macrophage infiltration upon transgenic
expression of M-CSF in the mammary epithelium restored pro-
gression of primary tumors to the stages of invasive carcinoma
(97). In fact, macrophages and tumor cells in mammary tumors
were documented to be comigratory and to be mutually dependent
for invasion and for cancer cell intravasation (90, 123). Hereby,
M-CSF produced by carcinoma cells promotes the expression of
EGF by macrophages, which in turn promotes the formation of
elongated protrusions and cell invasion by carcinoma cells. In
addition, EGF promotes the expression of M-CSF by carcinoma
cells, thereby generating a positive feedback loop. Disruption of
this paracrine amplification loop by blockade of either EGF recep-
tor or M-CSFR signaling was found to be sufficient for inhibiting
both macrophage and tumor cell migration and invasion (91).
A similar EGF/M-CSF paracrine interaction with macrophages,
resulting in enhanced cancer cell invasion as reported for murine
carcinoma cells, was confirmed in a mouse xenograft model of
human breast tumor derived cancer cells. Yet, for these human
breast carcinoma cells, the EGF/M-CSF paracrine feedback loop
was found to be complemented by autocrine M-CSF signaling
in the cancer cells (124). These data correlated with the expres-
sion of M-CSFR by human but not mouse breast carcinoma cells.
The possibility of macrophage-independent effects of M-CSF on
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human cancer cell invasion is also supported by a direct stimula-
tion of in vitro invasive capacity, but not proliferation, of human
adenocarcinoma cell lines by recombinant human M-CSF (125).
The studies in csf1op/op mice also indicated a role of M-CSF
in enhancement of metastatic growth of cancer cells. In par-
ticular, M-CSF was shown to be required for the recruitment
of a population of CD11b+F4/80+Gr1+ host macrophages to
extravasating pulmonary metastatic cells in the PyMT model.
This recruited CD11b+F4/80+Gr1+ macrophage population dis-
played a distinct phenotype as compared to CD11b−, CD11c+
lung resident macrophages and also did not express Tie2, render-
ing them distinct from the M-CSF-induced pro-angiogenic Tie2-
expressing monocytes/macrophages. The recruited macrophages
enhanced cancer cell metastasis through effects on cancer cell
metastatic seeding, extravasation, survival, and subsequent growth
(126). The authors confirmed that the reduced metastasis in
csf1op/op PyMT mice could be recapitulated in wild-type PyMT
mice via macrophage ablation using clodronate-containing lipo-
somes. Importantly, even after metastatic growth had been estab-
lished, macrophage ablation using clodronate-containing lipo-
somes inhibited subsequent metastatic growth (126). This effect
also seems to be M-CSF-specific since transgenic expression of
M-CSF in the mammary epithelium of both csf1op/op and wild-
type tumor-prone mice led to an acceleration to the late stages
of carcinoma and to a significant increase in pulmonary metasta-
sis. The clinical significance of these findings is illustrated by the
observation that the density of close tripartite interactions between
cancer cells, macrophages, and endothelial cells (tumor microen-
vironment of metastasis or TMEM) is predictive of metastasis
formation in breast cancer patients (127).
Since M-CSF signaling not only plays a critical role in the
turnover of TAM, but is also crucial for osteoclasts, blocking
M-CSFR signaling may not only attenuate metastasis via effects
on TAM, but may have additional beneficial effects on metasta-
tic disease via inhibitory effects on osteoclasts. As an example
of this, the AFS98 M-CSFR blocking mAb was recently docu-
mented to potently block the differentiation of osteoclasts and
their bone destruction activity in a breast cancer model of bone
metastasis (101).
A recent study placed a cautionary note on blocking M-CSFR
signaling as a therapeutic modality in cancer. In that study, mice
bearing two independently derived mammary cancer cell lines
(4T1.2 and EMT6.5) injected orthotopically into the mammary
gland, were treated with the AFS98 neutralizing anti-M-CSFR
mAb, with a neutralizing anti-mouse M-CSF mAb, or with two
different small molecule inhibitors of M-CSFR (GW2580 or
CYC11645). The authors observed variable effects on reduction
of TAM in the primary tumors or metastatic lung tissue, whereby
TAM could be reduced using GW2580 or high dose of AFS98,
but were not reduced when using lower dose of AFS98. Yet in
all these cases, not only did these various modalities for block-
ing M-CSFR not reduce primary tumor growth, but the intended
treatment actually increased metastasis to the lung and spine (66).
The authors found that the increased spontaneous metastasis upon
blocking of M-CSFR or M-CSF was associated with increased
levels of serum granulocyte-colony-stimulating factor (G-CSF),
increased numbers of neutrophils and Ly6Chigh monocytes in the
peripheral blood and increased frequency of neutrophils in the
primary tumor and in the lung. It is currently unclear why M-
CSFR blockade resulted in increased G-CSF levels in this model,
but the authors did observe that blood neutrophil numbers were
proportional to the metastatic capacity of the different mammary
carcinomas evaluated, suggesting that certain carcinomas may be
more prone to mobilize neutrophils, and leading to increased
metastasis. Interestingly, combining blockade of M-CSFR sig-
naling with a neutralizing antibody against the G-CSF receptor
(G-CSFR), which regulates neutrophil development and function,
reduced the enhanced metastasis, and neutrophil numbers that
resulted from M-CSFR blockade. In fact, the combined blocking of
M-CSFR and G-CSFR resulted in significantly reduced metastasis
as compared to the control condition (66).
POTENTIATION OF RADIO-, CHEMO-, AND IMMUNOTHERAPY
Whereas the M-CSFR inhibitors GW2580 or PLX3397 on their
own were reported to have little effect on tumor growth in murine
prostate cancer models, when added to radiotherapy, the M-CSFR
inhibitors suppressed tumor growth more effectively than radi-
ation alone (116). The synergistic effect of M-CSF blockade on
the efficacy of radiotherapy was explained by the observation that
irradiation resulted in increased M-CSF levels due to recruitment
of the DNA damage-induced kinase ABL1 into cell nuclei where it
bound the csf1 gene promoter and enhanced csf1 gene transcrip-
tion. Consequently, enhanced recruitment of TIM, including TAM
and MO-MDSC-like and PMN-MDSC-like cells, was detected and
this enhanced TIM recruitment was counteracted via the M-CSFR
inhibitors (116). These results suggest that blockade of the M-
CSF/M-CSFR axis can be a promising approach for developing
more effective combination cancer therapies. The authors sup-
ported the human relevance of these findings by reporting that also
in prostate cancer patients, serum levels of M-CSF were increased
after radiotherapy.
Such potential synergistic effects in combination therapy are
not only restricted to radiotherapy, but also extend to chemother-
apy. Indeed, combination therapy with a murinized, polyethyl-
ene glycol-linked antigen-binding fragment against mouse (host)
M-CSF reportedly reversed chemoresistance in athymic nude,
immunodeficient mice bearing human, and chemoresistant MCF-
7 breast cancer xenografts (99). Also treatment with the AFS98
anti-M-CSFR monoclonal antibody in mice already bearing estab-
lished PyMT tumors was reported to prolong their survival and
potentiate the effect of chemotherapy with Paclitaxel (101). Finally,
GW2580 or PLX3397 were found to improve chemotherapeutic
efficacy in mice bearing murine pancreatic ductal adenocarcinoma
cell lines. In this tumor model, gemcitabine chemotherapy was
documented to increase M-CSF levels and consequently enhance
the tumor infiltration of T-cell suppressive TAM (and MO-MDSC-
like cells). This effect was blunted when chemotherapy was com-
bined with M-CSFR blockade, resulting in increased anti-tumor
CD8+ T-cell responses and improved inhibition of tumor growth
and metastasis as compared to chemotherapy as monotherapy.
Accordingly, the higher therapeutic efficacy of combined treat-
ment with GW2580 plus gemcitabine compared with the effects
of gemcitabine alone was shown not to occur upon depletion of
CD8+ T lymphocytes (105).
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Considering the above, it comes as no surprise that, in the
same mouse model of pancreatic ductal adenocarcinoma, M-
CSFR signaling blockade using PLX3397 or GW2580 was shown
to enhance the therapeutic efficacy of so-called T-cell checkpoint
immunotherapy using PD1 and CTLA4 antagonists in combi-
nation with gemcitabine (114). In this case, M-CSFR signal-
ing blockade was reported to result in preferential depletion of
MMRhigh M2-like TAM and reprograming of the phenoptype of
the remaining TAM, with alleviated immunosuppressive activities
and enhanced antigen presentation capacity and which in turn
correlated with enhanced CD4+ and CD8+ T cell responses. Here
also, the increased therapeutic efficacy of the combination treat-
ment was shown to be blunted upon depletion of CD4+ and CD8+
T cells (114). As another example of a synergistic effect of M-
CSFR blockade on immunotherapy, PLX3397 has been reported
to improve the efficacy of adoptive cell therapy of melanoma-
targeted T cells in a syngeneic mouse model of BRAFV600E-driven
melanoma. Mice receiving the combined treatment produced
superior anti-tumor responses and exhibited improved overall
survival compared with single treatments, correlating with a dra-
matic reduction of TAM (but in this setting no significant change
in already low numbers of MO-MDSC-like or PMN-MDSC-like
cells), a skewing of the subpopulation balance in the remaining
TAM from predominant M2-oriented MHC-IIlow to predomi-
nant M1-oriented MHC-IIhigh macrophages and an increase in
tumor-infiltrating lymphocytes and T cells. The authors con-
clude that macrophages are the targets of PLX3397 by confirming
that PLX3397 and macrophage-depleting clodronate-containing
liposomes have the same effect on tumor growth and that this
effect is not further increasing when combining both depletion
methods (113).
CONCLUDING REMARKS AND CLINICAL PERSPECTIVES
Macrophage-colony-stimulating factor receptor inhibitors are
currently in clinical development as cancer therapeutics. Plexxicon
has, for example, initiated several clinical trials of the cKit and M-
CSFR inhibitor PLX3397, either as a stand-alone cancer treatment
(128–130) or in an adjuvant setting with chemo- and/or radio-
therapy (131–134). Phase I clinical trials of anti-M-CSFR mAbs in
patients with advanced solid tumors are currently being conducted
by Eli Lilly and Company for the fully human IgG1 IMC-CS4
(107) and by Roche for the humanized IgG1 RG7155 (135). For
the latter, it was mentioned in a recent publication that, based on
preliminary results of an ongoing clinical trial, administration of
RG7155 to diffuse-type giant cell tumor patients led to significant
reductions of M-CSFR+CD163+ macrophages in tumor tissues,
which correlated with at least partial clinical objective responses
(106). The ultimate value of these M-CSFR targeted therapies
will need to be assessed in follow-up studies aimed at demon-
strating effects that go beyond reduction in the primary tumor
burden, but extend to attenuation of metastasis and prolongation
of patient survival.
In this context, it is encouraging that numerous studies in
preclinical tumor models have revealed that blocking M-CSFR
signaling, despite variable effects on primary tumor growth per se,
has the potential to attenuate tumor-promoting effects of TAM
on tumor angiogenesis and cancer cell invasion and metastasis.
And especially, synergistic effects of M-CSFR blocking agents
in diminishing TAM-dependent resistance to anti-angiogenic
therapy, radiotherapy, chemotherapy, or immunotherapy offer
promising perspectives for effective combination therapy. Recent
studies thereby suggest that intratumoral M-CSF levels and their
balance with GM-CSF levels are not only critical for TAM dif-
ferentiation and maintenance, but can also contribute to shaping
the M1/M2 phenotypic and subpopulation heterogeneity of TAM.
Hence, M-CSFR blocking agents may not only have the poten-
tial to counteract cancer progression by reducing TAM content in
tumors and metastatic lesions, but also by re-educating TAM from
tumor-promoting toward anti-tumoral effector populations.
Recently, more attention is in addition being given to bet-
ter characterize other tumor-infiltrating myeloid cell populations
such as MDSC-like cells that are also affected by M-CSFR blockade
and to evaluate whether these contribute to the observed effects
of M-CSFR blockade on various aspects of cancer progression.
Additional effects on other cells are not necessarily a disadvantage
in the context of anti-cancer therapeutic activity, as exemplified
in reported attenuation of metastatic disease via dual inhibitory
effects on TAM and osteoclasts (101). Yet, the data recently
reported by Swierczak and colleagues on neutrophil-dependent
enhanced metastasis upon M-CSFR blockade (66) indicate that
blocking M-CSFR signaling may have variable effects according to
the tumor model and may in some cases exhibit unwanted side
effects. These cautionary findings are testaments to the notion
that successful clinical translation will be critically dependent on
proper patient stratification to focus on those patient groups in
which high M-CSF or M-CSFR expression is linked to disease
pathophysiology and correlates with worse prognosis and in which
M-CSFR/macrophage-targeted therapies are thus most likely to
exert a beneficial effect.
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